[
1. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches. Lancet Nerol. 2021;20(1):68-80.10.1016/S1474-4422(20)30412-9
]Search in Google Scholar
[
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002; 297:353-6.10.1126/science.107299412130773
]Search in Google Scholar
[
3. Dasari M, Espargaro A, Sabate R, Lopez Del Amo JM, Fink U, Grelle G, et al. Bacterial inclusion bodies of Alzheimer’s disease β-amyloid peptides can be employed to study native-like aggregation intermediate states. Chembiochem. 2011;12:407-23.10.1002/cbic.20100060221290543
]Search in Google Scholar
[
4. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta. 2011;1812:1359-70.10.1016/j.bbadis.2011.08.005318517221871956
]Search in Google Scholar
[
5. Govoni S, Mura E, Preda S, Racchi M, Lanni C, Grilli M, et al. Dangerous liaisons between beta-amyloid and cholinergic neurotransmission. Curr Pharm Des. 2014;20:2525-38.10.2174/1381612811319999050323859550
]Search in Google Scholar
[
6. Tang BL. Amyloid Precursor Protein (APP) and GABAergic neurotransmission. Cells. 2019;8:550.10.3390/cells8060550662794131174368
]Search in Google Scholar
[
7. Girek M, Szymański P. Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities. Chem Papers. 2018;73:269-89.10.1007/s11696-018-0590-8
]Search in Google Scholar
[
8. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48:6523-43.10.1021/jm058225d16220969
]Search in Google Scholar
[
9. Skalicka-Woźniak K, Orhan IE, Cordell GA, Nabavi SM, Budzyńska B. Implication of coumarins towards central nervous system disorders. Pharmacol Res. 2016;103:188-203.10.1016/j.phrs.2015.11.02326657416
]Search in Google Scholar
[
10. Rao VR. Antioxidant Agents. Advances in structure and activity relationship of coumarin derivatives. London; 2016:137-50.10.1016/B978-0-12-803797-3.00007-2
]Search in Google Scholar
[
11. Wang L, Yin YL, Liu XZ, Shen P, Zheng YG, Lan XR, et al. Current understanding of metal ions in the pathogenesis of Alzheimer’s disease. Transl Neurodegener. 2020;9 :10.10.1186/s40035-020-00189-z
]Search in Google Scholar
[
12. Budzynska B, Boguszewska-Czubara A, Kruk-Slomka M, Skalicka-Wozniak K, Michalak A, Musik I, et al. Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Psychopharmacology (Berl). 2015;232:931-42.10.1007/s00213-014-3728-6
]Search in Google Scholar
[
13. Espargaró A, Medina A, di Pietro O, Muñoz-Torrero D, Sabate R. Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. Scientific Reports. 2016;6:1-8.10.1038/srep23349
]Search in Google Scholar
[
14. Kowalczyk J, Budzyńska B, Kurach Ł, Pellegata D, Sayed NS, Gertsch J, et al. Neuropsychopharmacological profiling of scoparone in mice. Sci Rep. 2022;12:822.10.1038/s41598-021-04741-3
]Search in Google Scholar
[
15. Kozioł E, Skalicka-Woźniak K. Imperatorin–pharmacological meaning and analytical clues: profound investigation. Phytochem Rev. 2016;15:627-49.10.1007/s11101-016-9456-2
]Search in Google Scholar
[
16. Espargaró A, Sabaté R, Ventura S. Kinetic and thermodynamic stability of bacterial intracellular aggregates. FEBS Letters. 2008;582: 3669-73.10.1016/j.febslet.2008.09.049
]Search in Google Scholar
[
17. Espargaró A, Pont C, Gamez P, Muñoz-Torrero D, Sabate R. Amyloid pan-inhibitors: One family of compounds to cope with all conformational diseases. ACS Chem Neurosci. 2019;10:1311-7.10.1021/acschemneuro.8b00398
]Search in Google Scholar
[
18. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155:853-62.10.1016/S0002-9440(10)65184-X
]Search in Google Scholar
[
19. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535-9.10.1038/416535a11932745
]Search in Google Scholar
[
20. Li JJ, Dolios G, Wang R, Liao FF. Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression. PLoS One. 2014;9(3):e90770.10.1371/journal.pone.0090770394247824595404
]Search in Google Scholar
[
21. Yang J, Zhu B, Yin W, Han Z, Zheng C, Wang P, et al. Differentiating Aβ40 and Aβ42 in amyloid plaques with a small molecule fluorescence probe. Chem Sci. 2020;11:5238-45.10.1039/D0SC02060E
]Search in Google Scholar
[
22. Gu L, Guo Z. Alzheimer’s Aβ42 and Aβ40 peptides form interlaced amyloid fibrils. J Neurochem. 2013;126:305.10.1111/jnc.12202371683223406382
]Search in Google Scholar
[
23. Takomthong P, Waiwut P, Yenjai C, Sripanidkulchai B, Reubroycharoen P, Lai R, et al. Structure-activity analysis and molecular docking studies of coumarins from Toddalia asiatica as multifunctional agents for Alzheimer’s disease. Biomedicines. 2020;8(5):107.10.3390/biomedicines8050107727774832370238
]Search in Google Scholar
, 